Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-Guided Everolimus in HR+ Breast Cancer, PNET, and RCC
NCT02273752Phase 2Terminated
- Sponsor
- Emory University
- Start
- Nov 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in breast cancer, Pancreatic neuroendocrine tumor (PanNET) and renal cell carcinoma (RCC), sponsored by Emory University. Primary endpoint: Incidence of Stomatitis at Day 29. Started Nov 2014; status: terminated.
02
Drugs
everolimus
03
Conditions
breast cancerPancreatic neuroendocrine tumor (PanNET)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02273752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273752.